Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kos settles Advicor name dispute with Andrx

Executive Summary

Andrx will end use of the Altocor name and pay $6 mil. to settle trademark dispute over Kos' cholesterol product Advicor. Settlement ends litigation in Philadelphia federal appeals court. Kos' original complaint in New Jersey federal court sought to enjoin Andrx from using Altocor name for its extended-release lovastatin; that motion was denied. Andrx will now market its product as Altoprev, a name approved by FDA in August 2003 (1"The Pink Sheet" May 10, 2004, In Brief)...

You may also be interested in...

Andrx changing Altocor name

Andrx is in discussions with FDA to market Altocor (lovastatin extended-release) under a new name "to avoid possible confusion in the marketplace." Company says name change is unrelated to Kos' lawsuit alleging a likelihood of confusion with its cholesterol-lowering agent Advicor (niacin/lovastatin). FDA already has approved Altoprev as an alternative brand for Altocor (1"The Pink Sheet" Sept. 15, 2003, In Brief)...

European SEAC Opinion Unchanged: Microplastics Must Be Out Of All Cosmetics Within Six Years

The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.

QUOTED. 2 March 2021. Michael Coyle.

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts